Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
PqFTR1S2bHfaRFJa